These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 2447434

  • 1. Altered adrenergic control in hypercholesterolemia.
    Ohanian J, Nicolosi RJ, Vatner SF, Graham RM, Kowala MC, Young MA.
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S11-5. PubMed ID: 2447434
    [Abstract] [Full Text] [Related]

  • 2. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism.
    Krone W, Müller-Wieland D, Nägele H, Behnke B, Greten H.
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S199-202. PubMed ID: 2455133
    [Abstract] [Full Text] [Related]

  • 3. Metabolic changes during antihypertensive therapies.
    Krone W, Nägele H.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [Abstract] [Full Text] [Related]

  • 4. Regulation of lipoprotein metabolism by adrenergic mechanisms.
    Dzau VJ, Sacks FM.
    J Cardiovasc Pharmacol; 1987 Dec; 10 Suppl 9():S2-6. PubMed ID: 2447436
    [Abstract] [Full Text] [Related]

  • 5. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation.
    Baldassarre D, Mores N, Colli S, Pazzucconi F, Sirtori CR, Tremoli E.
    Clin Pharmacol Ther; 1997 Jun; 61(6):684-91. PubMed ID: 9209252
    [Abstract] [Full Text] [Related]

  • 6. Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia.
    Yashiro A, Sugano M, Nakashima Y, Tasaki H, Kuroiwa A.
    Clin Ther; 1987 Jun; 10(1):98-106. PubMed ID: 2897239
    [Abstract] [Full Text] [Related]

  • 7. Antihypertensive drugs and blood lipids: the Oslo study.
    Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG.
    J Cardiovasc Pharmacol; 1982 Jun; 4 Suppl 2():S222-4. PubMed ID: 6177960
    [Abstract] [Full Text] [Related]

  • 8. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
    Foxall TL, Shwaery GT, Stucchi AF, Nicolosi RJ, Wong SS.
    Am J Pathol; 1992 Jun; 140(6):1357-63. PubMed ID: 1351367
    [Abstract] [Full Text] [Related]

  • 9. Effect of alpha/beta blockers on serum lipids.
    Lehtonen A.
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):228-30. PubMed ID: 6114045
    [Abstract] [Full Text] [Related]

  • 10. Effects of alpha 1-inhibition on lipid metabolism in the rat.
    Woodside WF, Swindell AC.
    J Cardiovasc Pharmacol; 1987 May; 10 Suppl 9():S27-34. PubMed ID: 2447438
    [Abstract] [Full Text] [Related]

  • 11. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys.
    Miyazaki M, Hosoki K, Okunishi H, Ishii K, Ikeno A, Okazaki Y.
    Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692
    [Abstract] [Full Text] [Related]

  • 12. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR.
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [Abstract] [Full Text] [Related]

  • 13. Effect of chronic treatment with atenolol and prazosin in streptozotocin induced diabetic rats.
    Goyal RK, Bangaru RA, Lakkad NB, Rao MV.
    Indian J Physiol Pharmacol; 1996 Jul; 40(3):220-4. PubMed ID: 8950136
    [Abstract] [Full Text] [Related]

  • 14. The effects of antihypertensive agents on serum lipids and lipoproteins.
    Lardinois CK, Neuman SL.
    Arch Intern Med; 1988 Jun; 148(6):1280-8. PubMed ID: 2897834
    [Abstract] [Full Text] [Related]

  • 15. [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
    Ponikowski P, Hańczycowa H, Sebzda T, Jurga M, Spring A, Rotter A, Jordanek P.
    Wiad Lek; 1993 Apr; 46(7-8):250-4. PubMed ID: 7902632
    [Abstract] [Full Text] [Related]

  • 16. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.
    Lehtonen A, Tanskanen A, Temmerman J.
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):448-51. PubMed ID: 2888737
    [Abstract] [Full Text] [Related]

  • 17. Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function.
    Jatwa R, Kar A.
    Eur J Pharmacol; 2006 Dec 03; 551(1-3):87-91. PubMed ID: 17027746
    [Abstract] [Full Text] [Related]

  • 18. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD.
    Clin Ther; 1994 Dec 03; 16(3):490-504. PubMed ID: 7923316
    [Abstract] [Full Text] [Related]

  • 19. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
    Karge WH, Kowala MC, Weiner EJ, Nicolosi RJ.
    J Cardiovasc Pharmacol; 1989 Dec 03; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
    [Abstract] [Full Text] [Related]

  • 20. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P, de Courten M, Ferrari P, Böhlen L.
    J Cardiovasc Pharmacol; 1993 Dec 03; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.